3 results
Approved WMORecruiting
To investigate whether mifepristone (7-day, 1200 mg/day) added to treatment as usual (TAU), is more efficacious than placebo in reducing depressive symptom severity (Inventory of Depressive Symptoms-Self Rated questionnaire; IDS-SR) in patients with…
Approved WMORecruiting
• To assess the tolerability and safety of the investigational medicinal product
Approved WMORecruiting
Our overall aim is to study how different pathological mechanisms in cerebral SVD influence WMH shape.Primary objectiveTo study the association of a more complex WMH shape with abnormalities in small vessel morphology.Secondary objectiveTo study the…